VivoSeq
Other

Long-Term Follow-up

0

Pipeline Programs↗

30

Active Trials↗

30

Companies Involved↗

Long-term Follow-up is an early-stage landscape with 0 programs across 30 companies. The most active players are GSK, Novartis, Sangamo Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

27/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalS

Sangamo Therapeutics

0 programs

PreclinicalG

Genocea Biosciences, Inc.

0 programs

PreclinicalM

March Biosciences Inc

0 programs

PreclinicalE

Excision BioTherapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

55

clinical trials

Completed16 · 29%
Enrolling by invitation13 · 24%
Active, not recruiting8 · 15%
Terminated8 · 15%
Recruiting6 · 11%
Not yet recruiting3 · 5%
Other1 · 2%

Clinical Trials

Trial Activity

55 trials

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
Recruiting·MMiltenyi Biomedicine GmbH·N/A·NCT06508775·40 enrolled
A Long-term Follow-up Study in Patients Who Received BEAM-101
Recruiting·Beam Therapeutics logoBeam Therapeutics·N/A·NCT07373639·50 enrolled
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Recruiting·KKyverna Therapeutics·N/A·NCT07403188·70 enrolled
A Long-Term Follow-Up Study of Participants Exposed to REACT
Recruiting·PProkidney·N/A·NCT05918523·80 enrolled
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Recruiting·UUSWM CT, LLC·Phase 1·NCT03391778·250 enrolled
Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration
Recruiting·PPharmicell Co., Ltd.·N/A·NCT07400458·100 enrolled
Long-Term Follow-up Study for Patients From AVXS-101-CL-101
Active, not recruiting·Novartis logoNovartis·N/A·NCT03421977·13 enrolled
Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
Active, not recruiting·PPoseida Therapeutics, Inc.·Phase 1·NCT03741127·100 enrolled
Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)
Active, not recruiting·SSpark Therapeutics, Inc.·N/A·NCT03602820·41 enrolled
Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy
Active, not recruiting·AstraZeneca logoAstraZeneca·N/A·NCT05506254·4 enrolled
Evaluation Safety and Explore Efficacy Long-term Follow-up Study on Subjects Receiving SMUP-IA-01 or Active Control
Active, not recruiting·MMedipost Co Ltd.·Phase 2·NCT06798727·84 enrolled
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination
Active, not recruiting·—·Phase 3·NCT06007183·800 enrolled
Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting
Active, not recruiting·Jazz Pharmaceuticals logoJazz Pharmaceuticals·N/A·NCT05772429·158 enrolled
Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)
Active, not recruiting·Novartis logoNovartis·Phase 1·NCT06155500·4 enrolled
A Long-term Follow-up Study of Patients Who Received MB-105
Not yet recruiting·MMarch Biosciences Inc·N/A·NCT07340814·40 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)